H2受体阻滞剂联合多潘立酮对肝硬化患者门脉血流的影响  

Effect of H2-receptor blocker combined with domperidone on the blood flow of portal venous system in patients with liver cirrhosis

作　　者：达炜[1] 陈金联[1] 朱金水[1] 陈尼维[1] 孙群[1] 陈维雄[1] 

机构地区：[1]上海交通大学附属第六人民医院消化内科,上海市200233

出　　处：《世界华人消化杂志》2007年第4期408-411,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨H2受体阻滞剂联合多潘立酮对肝硬化患者门静脉系统血流量的影响．方法:以20名健康人作为正常对照．60例肝硬化患者随机分成3组,分别给予口服高舒达、口服多潘立酮以及联合用药,治疗前后采用多普勒超声测定门静脉(PVF)、脾静脉(SVF)和肠系膜上静脉(SMVF)血流量(mL/min)．结果:治疗后,H2受体阻滞剂组的PVF显著高于治疗前(850．23±140．78 vs 695．22±221．44, P＜0．01),SVF和SMVF低于治疗前,但无显著差异．多潘立酮组PVF较治疗前有增高,无显著差异,而SVF和SMVF显著低于治疗前(SVF: 598．13±272．33 vs 816．40±279．61,P＜0．05: SMVF:504．23±188．54 vs 640．30±200．12．P＜0．05)．联合用药组则PVF显著高于治疗前(876．76±178．65 vs 705．34±200．15,P＜0．05),而SVF、SMVF显著低于治疗前(SVF:605．33±252．86 vs 798．33±280．45,P＜0．01:SMVF: 503．43±175．25 vs 650．19±190．62,P＜0．01)．结论:H2受体阻滞剂组及多潘立酮都具有改善门静脉系统血流的作用,联合应用作用更为明显．AIM： To explore the effect of H2-receptor blocker combined with domperidone on the blood flow of portal venous system in patients with liver cirrhosis. METHODS： A total of 60 patients with liver cirrhosis were randomly and averagely divided into group A, B, and C, treated with H2-receptor blocker, domperidone, and their combination, respectively. Twenty healthy subjects served as normal controls. Portal venous flow （PVF, mL/min）, splenic venous flow （SVF, mL/min） and superior mesenteric venous flow （SMVF, mL/min） were determined using Doppler ultrasonography before and after treatment. RESULTS： After treatment, PVF was significantly higher than that before treatment （850.23 ± 140.78 vs 695.22 ±221.44, P 〈 0.01）, while SVF and SMVF were lower （both P 〉 0.05） in groupA. PVF was increased as compared with that before treatment in group B, but there was no significant difference （P 〉 0.05）. However, SVF and SMVF were markedly decreased as compared with those before treatment in group B （SVF： 598.13 ± 272.33 vs 816.40 ± 279.61, P 〈 0.05; SMVF： 504.23 ± 188.54 vs 640.30 ± 200.12, P 〈 0.05）. PVF was remarkably higher than that before treatment （876.76 ± 178.65 vs 705.34 ± 200.15, P 〈 0.05）, while SVF and SMVF were lower （SVF： 605.33 ± 252.86 vs 798.33 ± 280.45, P 〈 0.01; SMVF： 503.43 ±175.25 vs 650.19 ± 190.62, P 〈 0.01） in group C. CONCLUSION： H2-receptor blocker and domperidone can improve the blood flow of portal venous system, and their combination is more effective.

关 键 词：肝硬化 门脉系统 H2受体阻滞剂 多潘立酮 多普勒超声 

分 类 号：R575.2[医药卫生—消化系统]